Moderna
Q4 2022 Earnings Call
Feb 23, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning. My name is Kevin and welcome to Moderna's fourth quarter 2022 earnings call. [Operator instructions] Following the formal remarks, we'll open the call for your questions. [Operator instructions] Please be advised, this call is being recorded.
At this time, I would like to turn the call over to Lavina Talukdar, head of investor relations at Moderna. Please proceed.
Lavina Talukdar -- Head of Investor Relations
Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's fourth quarter and full year 2022 financial results and business updates. You can access the press release issued this morning, as well as the slides that we'll be reviewing, by going to the investors section of our website. On today's call are Stéphane Bancel, our chief executive officer; Stephen Hoge, our president; Arpa Garay, our chief commercial officer; and Jamie Mock, our chief financial officer.
Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance or results to differ materially from those expressed or implied in these forward-looking statements. With that, I will now turn the call over to Stephane.
Stéphane Bancel -- Chief Executive Officer
Thank you, Lavina. Good morning or good afternoon, everyone. Welcome to our Q4 2022 conference call. Today, I will start with a quick business review of 2022.
Stephen will then review our clinical programs before Arpa gives an update on the commercial progress and plans. Jamie will then present the financial results, and I will come back to share some thoughts on where we're heading. We are pleased to report today revenues of $19.3 billion for fiscal year 2022, GAAP net income of 8.4 billion, and GAAP diluted earnings per share of $20.12. Cash and investment balances of 18.2 billion at the end of the year.
We continued our disciplined capital allocation policy, reinvesting first in our company. In 2022, we invested $3.3 billion in R&D, our highest level of R&D investment ever. We invested 1.1 billion in SG&A and 400 million in capital investments. We made investments in Metagenomi for access to new gene-editing enzymes and Carisma in oncology.